From Investing.com:

Hansa Biopharma expects to report SEK 50 million in Q4 2023 revenue, driven by SEK 43 million from Idefirix® sales in the U.K., Germany, and Spain. Clinical trials for kidney transplantation and anti-GBM disease are making progress with 101 and 16 patients enrolled respectively, while new trials for other rare diseases are also underway.

Additionally, the company has entered a commercial partnership with NewBridge Pharmaceuticals to supply Idefirix® to kidney transplant patients in the MENA region using existing European marketing authorization.

Hansa Biopharma has initiated the first-in-human trial for HNSA-5487 and is conducting further analysis, including immunogenicity, to inform future clinical development. A phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 gene therapy for Duchenne Muscular Dystrophy has also started in December 2023.

Despite operating losses of SEK 177 million for Q4 2023 and SEK 790 million for the full year, Hansa Biopharma maintains a strong cash position of SEK 732 million as of December 31, 2023, with research and development expenses reaching SEK 411 million.

Key financial milestones for 2024 include high-level data readout from the phase 1b study in DMD with Sarepta and the completion of randomization for the U.S. ConfIdeS phase 3 trial. The full Q4 2023 interim report will be published on February 2, 2024.

Hansa Biopharma’s management will be available for meetings during the J.P. Morgan Conference week from January 8-11, 2024, to discuss these developments. This business update is based on a press release statement and preliminary financials.



Read more: Hansa Biopharma reports robust Q4 with SEK 50m revenue By Investing.com